Impact of unbalanced karyotypes at diagnosis on prognosis of CML.

被引：0
|
作者：
Hehlmann, Ruediger
Kalmanti, Lida
Dietz, Christian
Lauseker, Michael
Haferlach, Claudia
Schlegelberger, Brigitte
Jotterand, Martine
Mueller, Martin C.
Haenel, Mathias
Koehne, Claus-Henning
Goebeler, Maria-Elisabeth
Pfreundschuh, Michael
Balleisen, Leopold
Burchert, Andreas
Krause, Stefan W.
Pfirrmann, Markus
Hasford, Joerg
Hochhaus, Andreas
Saussele, Susanne
Fabarius, Alice
机构：
[1] Heidelberg Univ, Med Fak Mannheim, Mannheim, Germany
[2] Univ Munich, Inst Med Informat Verarbeitung Biometrie & Epidem, Munich, Germany
[3] MLL, Munich, Germany
[4] Hannover Med Sch, Inst Zell & Mol Pathol, D-30623 Hannover, Germany
[5] Serv Genet Med, Lausanne, Switzerland
[6] Klinikum Chemnitz, Innere Med Klin 3, Chemnitz, Germany
[7] Klinikum Oldenburg, Klin Onkol & Hamatol, Oldenburg, Germany
[8] ZIM, Med Klin 2, Wurzburg, Germany
[9] Univ Klinikum Saarlandes, Homburg, Saar, Germany
[10] Evangel Krankenhaus Hamm, Hamatol Onkol Abt, Hamm, Germany
[11] Univ Klinikum Giessen & Marburg GmbH, Standort Marburg, Marburg, Germany
[12] Univ Klinikum Erlangen, Med Klin 5, Erlangen, Germany
[13] Univ Klinikum Jena, Jena, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7041
引用
收藏
页数：1
相关论文
共 50 条
  • [41] GM-CSF improves activity of interferon as primary therapy for CML.
    Smith, BD
    Matsui, WH
    Murphy, K
    Gladstone, DE
    Jones, RJ
    BLOOD, 2004, 104 (11) : 253B - 253B
  • [42] Use of computational combinatorial chemistry to develop chemical inhibitors of oncoproteins in CML.
    Deisseroth, A
    Guo, XY
    Liu, F
    Wang, T
    Lerma, E
    Savinov, S
    Austin, D
    EXPERIMENTAL HEMATOLOGY, 1999, 27 (07) : 137 - 137
  • [43] Impact of recipient CMV status on outcome after T-depleted volunteer unrelated donor (VUD) transplantation for CML.
    Craddock, C
    Szydlo, R
    Ward, K
    Yong, A
    Brookes, P
    Kanfer, E
    Apperley, J
    Goldman, J
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 : 69 - 69
  • [44] Intensive treatment in order to minimize the Ph-positive clone in CML.
    Simonsson, B
    Oberg, G
    Linder, O
    Bjorkholm, M
    Carneskog, J
    Stenke, L
    Karle, H
    LanngNielsen, J
    Lofvenberg, E
    Malm, C
    Paul, C
    Turesson, I
    Uden, AM
    Vilen, L
    WeisBjerrum, O
    BLOOD, 1997, 90 (10) : 1744 - 1744
  • [45] Autologous transplantation of in-vivo purged PBSC in chronic phase CML.
    Fischer, T
    Mohm, J
    Duyster, J
    Busemann, C
    Huhn, D
    Bunjes, D
    Neubauer, A
    Ehninger, G
    Kolbe, K
    Hehlmann, R
    Huber, C
    BLOOD, 1999, 94 (10) : 143A - 143A
  • [46] Life-threatening immune pancytopenia after mud BMT for CML.
    Onida, F
    Pozzoli, E
    Tagliaferri, E
    Annaloro, C
    Della Volpe, A
    Deliliers, GL
    BONE MARROW TRANSPLANTATION, 1998, 21 : S33 - S33
  • [47] ATOMIC BOMBS, RADIATION THERAPY AND CML. SOMETHING'S ROTTEN IN DENMARK
    Gale, Robert Peter
    LEUKEMIA RESEARCH, 2014, 38 : S3 - S3
  • [48] The genetic instability of mismatch repair gene linked microsatellite and the evolution of CML.
    Li, G
    Song, YH
    Wang, MH
    Ma, XT
    Qian, LS
    Wu, KF
    EXPERIMENTAL HEMATOLOGY, 1999, 27 (07) : 78 - 78
  • [49] Design and development of ponatinib, a pan-BCR-ABL inhibitor for CML.
    Clackson, Tim
    CANCER RESEARCH, 2013, 73 (08)
  • [50] Acquired homozygosity for t(9;22) during clonal evolution in CML.
    Wisniewski, L
    Papenhausen, P
    Tepperberg, J
    Mowrey, P
    Singh-Kahlon, P
    Gadi, I
    Moscinski, L
    AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (05) : 225 - 225
12345